Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881143 | 0.91 | KDM4E (0.45) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL11473929 | 0.87 | KDM4E (0.45) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL24440339 | 0.86 | KDM4E (0.48) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL24074659 | 0.85 | ALDH1A1 (0.57) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL6274334 | 0.84 | MEN1 (0.55) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL29266193 | 0.83 | ALDH1A1 (0.47) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL22445329 | 0.83 | BDKRB1 (0.44) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL1802101 | 0.83 | ALDH1A1 (0.44) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL11355913 | 0.83 | GABRA1 (0.42) | KDM4EKMT2AMEN1HTTSMN1; SMN2 | |
| Hydroxyamine SCHEMBL31418669 | 0.82 | MEN1 (0.53) | KDM4EKMT2AMEN1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2710045-A1 | HALOGEN FREE THERMOSET RESIN SYSTEM FOR LOW DIELECTRIC LOSS AT HIGH FREQUENCY APPLICATIONS | Huntsman Advanced Materials Americas LLC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20140057086-A1 | Halogen Free Thermoset Resin System for Low Dielectric Loss at High Frequency Applications | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012158415-A1 | HALOGEN FREE THERMOSET RESIN SYSTEM FOR LOW DIELECTRIC LOSS AT HIGH FREQUENCY APPLICATIONS | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| US-7803298-B2 | Molding material, molded part, and method for manufacturing them | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7759356-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7754730-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090085260-A1 | BIODEGRADABLE MATERIAL AND PROCESS FOR PRODUCING THE SAME | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090030160-A1 | Polylactic Acid Complex and Production Method Thereof | SUMITOMO ELECTRIC FINE POLYMER INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080213209-A1 | Process for Producing Cross-Linked Material of Polylactic Acid and Cross-Linked Material of Polylactic Acid | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080036119-A1 | Molding material, molded part, and method for manufacturing them | SUMITOMO ELECTRIC FINE POLYMER, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20060160984-A1 | Biodegradable material and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050242466-A1 | Process for producing transparent material made of polylactic acid and transparent material made of polylactic acid | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005042500-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | KDM4E 2705/4885KMT2A 2094/4885MEN1 3809/4885 |
| US-20090085260-A1 | BIODEGRADABLE MATERIAL AND PROCESS FOR PRODUCING THE SAME | TST, PCMT1, XRCC6 | KDM4E 2178/4885KMT2A 1444/4885MEN1 214/4885 |
| US-20090054429-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | KDM4E 2705/4885KMT2A 2094/4885MEN1 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.